Novartis On Payer Contracts, Other Updates From BIO CEO & Investor Conference
This article was originally published in The Pink Sheet Daily
Novartis' recent arrangements with Cigna and Aetna tying Entresto reimbursement to outcomes, new Gilead hires and a potential labeling change for Relypsa's Veltassa.
You may also be interested in...
Novartis and Amgen are trying to build a compelling case for the value of their CGRP antagonist erenumab. Novartis said one strategy under consideration is to underwrite the cost of the drug for patients who don't respond.
Shaw is the former US President of rival Novartis and a rising figure in big pharma. She will take over the role previously held by Ricks, who became CEO Jan. 1. Conterno will assume President USA role.
Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.